MedPath

Amgen Manufacturing, Limited

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

94

Active:4
Completed:69

Trial Phases

4 Phases

Phase 1:27
Phase 2:24
Phase 3:29
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (86 trials with phase data)• Click on a phase to view related trials

Phase 3
29 (33.7%)
Phase 1
27 (31.4%)
Phase 2
24 (27.9%)
Phase 4
6 (7.0%)

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Phase 1
Recruiting
Conditions
Thyroid Eye Disease
Interventions
Other: Placebo
First Posted Date
2024-05-06
Last Posted Date
2025-07-28
Lead Sponsor
Amgen
Target Recruit Count
88
Registration Number
NCT06401044
Locations
🇦🇺

North Shore Private Hospital, Saint Leonards, New South Wales, Australia

🇦🇺

Macquarie University Hospital, Sydney, New South Wales, Australia

🇺🇸

Levenson Eye Associates, Jacksonville, Florida, United States

and more 2 locations

A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

Phase 1
Active, not recruiting
Conditions
Obesity
Interventions
First Posted Date
2024-04-08
Last Posted Date
2024-08-02
Lead Sponsor
Amgen
Target Recruit Count
20
Registration Number
NCT06352892
Locations
🇭🇰

Queen Mary Hospital, Hong Kong, Hong Kong

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2023-11-14
Last Posted Date
2025-06-05
Lead Sponsor
Amgen
Target Recruit Count
535
Registration Number
NCT06131398
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Alliance for Multispecialty Research - Kansas City, Merriam, Kansas, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 22 locations

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

Phase 3
Recruiting
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2023-10-18
Last Posted Date
2025-08-14
Lead Sponsor
Amgen
Target Recruit Count
50
Registration Number
NCT06088199
Locations
🇺🇸

Pediatric Skin Research LLC, Coral Gables, Florida, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Affiliated Dermatology, Scottsdale, Arizona, United States

and more 27 locations

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Phase 4
Active, not recruiting
Conditions
Postmenopausal Osteoporosis
Interventions
First Posted Date
2023-10-12
Last Posted Date
2024-11-18
Lead Sponsor
Amgen
Target Recruit Count
100
Registration Number
NCT06079476
Locations
🇮🇳

Sir Ganga Ram Hospital, New Delhi, Delhi, India

🇮🇳

Apollo Hospital, New Delhi, Delhi, India

🇮🇳

Stavya Spine Hospital and Research Institute SSHRI, Ahmedabad, Gujarat, India

and more 7 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 19
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.